抗体薬物複合体（ADC）の世界市場2015：パイプライン分析、技術動向、競争状況...市場調査レポートについてご紹介

Introduction 13
Executive Summary 13
Scope of the Report 14
Antibody-Drug Conjugate Introduction 15
Historical Perspective of Antibody-Drug Conjugate 15
Design of Antibody-Drug Conjugate 17
Different components of Antibody-Drug Conjugate 17
Immunocongugate–A distinct class of therapeutics in Oncology 20
Advantages of ADC over Traditional Therapies 21
Important Hurdles Faced in Development and Commercialization of ADC 22
Current scenario of Marketed and Pipeline Antibody-Drug Conjugate 23
Antibody-Drug Conjugate Marketed Scenario 23
Antibody-Drug Conjugate Pipeline Scenario 25
Current Therapy Areas under Research for Antibody-Drug Conjugate Development 28
Companies Involved in Antibody-Drug Conjugate Market 29
Big Pharmaceuticals companies showing interest in ADC market and why? 30
Companies with the Technology for Antibody-Drug Conjugate Products Development 32
Companies in Collaboration for Technology 34
Companies with Monoclonal Antibodies for the Antibody Drug Development 36
Companies in Collaboration for Monoclonal Antibodies 38
Geographical Distribution of Companies involved in ADC Drugs Development (Drug) 40
Geographical Distribution of Companies by Region 40
Geographical Distribution of Companies by Country 41
Antibody-Drug Conjugate Drugs under Different classes of Linkers 43
Marketed Antibody-Drug Conjugates and their Global Impact 45
Global Sales Assessment of Adcetris 45
Global Sales Assessment of Kadcyla 47
Global Sales Assessment of Mylotarg 49
Market Size Assessment of Antibody-Drug Conjugates 50
Antibody-Drug Conjugates in Pipeline 52
Report Methodology 340
Contact Us 342
Disclaimer 342
About DelveInsight 342

List of Tables
Table 1: Marketed and Pipeline Antibody-Drug Conjugates, 2015
Table 2: Antibody-Drug Conjugate in Pipeline by Phase, 2015
Table 3: Therapeutic Areas under Research for Antibody-Drug Conjugate Products, 2015
Table 4: Number of Companies Targeting Different Therapeutics Areas in Antibody-Drug Conjugate Market Globally, 2015
Table 5: Number of Companies Targeting Different Therapeutics Areas in Antibody-Drug Conjugate Market Globally, 2015
Table 6: Number of Technologies with Companies for Antibody-Drug Conjugate Products Development, 2015
Table 7: Number of Companies Technology for Antibody-Drug Conjugates Development, 2015
Table 8: Number of Companies with Monoclonal Antibodies for Antibody-Drug Conjugates Development, 2015
Table 9: Number of Companies Monoclonal Antibodies for Antibody-Drug Conjugates Development, 2015
Table 10: Geographical Distribution of Antibody-Drug Conjugate Products by Region, 2015
Table 11: Geographical Distribution of the ADC Drugs in Different Regions of the World, 2015
Table 12: Geographical Distribution of Antibody-Drug Conjugate Products in Different Regions of the World, 2015
Table 13: Adcetris, Global Sales from 2011 (in million USD), 2015
Table 14: Kadcyla, Global Sales from 2013 (in million USD), 2015
Table 15: Antibody-Drug Conjugate Global Sales (in million USD), 2015

List of Figures
Figure 1: Marketed and Pipeline Antibody-Drug Conjugates, 2015
Figure 2: Phase III Antibody-Drug Conjugates and Trials, 2015
Figure 3: Comparison Graph for Discovery and Pre-clinical Antibody-Drug Conjugates, 2015
Figure 4: Antibody-Drug Conjugate in Pipeline by Phase, 2015
Figure 5: Therapeutic Areas under Research for Antibody-Drug Conjugate Products, 2015
Figure 6: Total Number of Companies Targeting Different Therapeutics Areas in Antibody-Drug Conjugate Market Globally, 2015
Figure 7: Number of Companies Targeting Different Therapeutics Areas in Antibody-Drug Conjugate Market Globally, 2015
Figure 8: Number of Technologies with Companies for Antibody-Drug Conjugate Products Development, 2015
Figure 9: Number of Companies with Technology for Antibody-Drug Conjugates Development, 2015
Figure 10: Number of Companies with Monoclonal Antibodies for Antibody-Drug Conjugates Development, 2015
Figure 11: Number of Companies Collaboration for Monoclonal Antibodies for Antibody-Drug Conjugates Development, 2015
Figure 12: Geographical Distribution of Antibody-Drug Conjugate Products by Region, 2015
Figure 13: Geographical Distribution of Antibody-Drug Conjugate Products by Country, 2015
Figure 14: Geographical Distribution of the Antibody-Drug Conjugate Products in Different Regions of the World, 2015
Figure 15: Adectris, Global Sales from 2011 (in million USD), 2015
Figure 16: Kadcyla, Global Sales from 2013 (in million USD), 2015
Figure 17: Antibody-Drug Conjugate Global Sales (in million USD), 2015